Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN with or without laser versus laser for branch retinal vein occlusion macular edema
NL-OMON37792Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in branch retinal vein occlusion (BRVO) and macular edema (3 arms), sponsored by Novartis. Primary endpoint: Mean best-corrected visual acuity change at Month 6 from baseline. Started Aug 2012; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on NL-OMON37792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37792.